The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy

  title={The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy},
  author={R E J Roach and Willem M Lijfering and Frans M. Helmerhorst and S. C. Cannegieter and Frits Richard Rosendaal and Astrid van Hylckama Vlieg},
  journal={Journal of Thrombosis and Haemostasis},
Roach REJ, Lijfering WM, Helmerhorst FM, Cannegieter SC, Rosendaal FR, van Hylckama Vlieg A. The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy. J Thromb Haemost 2013; 11: 124–31. 

Prevention and treatment of venous thromboembolism during HRT: current perspectives

  • H. Rott
  • Medicine, Biology
    International journal of general medicine
  • 2014
Bioidentical hormone therapy via the transdermal route seems to be the safest opportunity for hormone replacement therapy, although large trials for bioidentical hormones therapy are needed.

Hormonal therapies and venous thrombosis: Considerations for prevention and management

Thrombosis risk is seen with both hormonal contraceptive agents and hormone replacement therapy for menopause and gender transition and over the past several decades large epidemiological studies have helped better define these risks.

Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta‐analysis

The results support discouraging COC‐use in women with a natural anticoagulant deficiency and additive risk of factor V Leiden (FVL) or prothrombin‐G20210A (PT) mutation is modest.

Venous thromboembolism in women: new challenges for an old disease

A nonsystematic review of recent literature evaluating and summarizing the associations between VTE and clinical situations peculiar to women and evaluating the patients’ contraindications, eligibility criteria, and autonomy.

Management of Menopausal Symptoms for Women Who Are at High Risk of Thrombosis.

Clinicians are challenged to relieve menopausal symptoms without increasing the risk of thrombosis with transdermal therapies and with progesterone over synthetic progestogens (progestins).

Venous Thromboembolism Issues in Women.

In women diagnosed with acute hormone-related VTE who are treated with oral anticoagulants, adequate contraception is mandatory to avoid unwanted pregnancies and current evidence and guideline recommendations are summarized.

Hormones and venous thromboembolism among postmenopausal women

  • P. Scarabin
  • Medicine
    Climacteric : the journal of the International Menopause Society
  • 2014
There is strong evidence that VTE risk is greater in women using medroxyprogesterone acetate compared with those receiving other progestins, and progesterone appears safe with respect to VTE.

The incidence and prognosis of thromboembolism associated with oral contraceptives: Age‐dependent difference in Japanese population

The incidence and prognosis of thromboembolism associated with combined oral contraceptives (COCs) by age groups in Japan by agegroups in Japan is analyzed.



Postmenopausal Hormone Therapy and Risk of Idiopathic Venous Thromboembolism: Results From the E3N Cohort Study

Oral estrogen therapy increases venous thromboembolism risk among postmenopausal women using hormone therapy and route of estrogen administration and concomitant progestogens type are 2 important determinants of thrombotic risk.

Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study

Oral but not transdermal estrogen is associated with an increased VTE risk, and data suggest that norpregnane derivatives may be thrombogenic, whereas micronized progesterone and pregnane derivatives appear safe with respect toThrombotic risk.

Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study

In contrast to oral estrogen, transdermal estrogen does not confer an additional risk of idiopathic VTE in women with increased BMI, and the safety of transDermal estrogen on thrombotic risk has to be confirmed.

Factor V Leiden, Hormone Replacement Therapy, and Risk of Venous Thromboembolic Events in Women With Coronary Disease

If factor V Leiden genotyping becomes less expensive, it could be cost effective to screen for the presence of the mutation before instituting HRT in women with coronary disease.

The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study

A high risk of venous thrombosis during the first months of oral contraceptive use irrespective of the type of oral contraceptives is confirmed, and many women do not use the safest brands.

Estrogen plus progestin and risk of venous thrombosis

Estrogen plus progestin therapy was associated with doubling the risk of venous thrombosis and the risks associated with age, overweight or obesity, and factor V Leiden were increased.

Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis

It is concluded that the thrombosis risk of HRT may particularly affect women with prothrombotic mutations, and efforts to avoid HRT in women with increased risk of thromBosis are advisable.

Postmenopausal Estrogen Replacement and Risk for Venous Thromboembolism

The venous thromboembolism risk with postmenopausal estrogen replacement therapy is estimated using a meta-analysis of eligible studies and fixed-effects and random-effects models using the Bayesian data analytic framework.